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Abstract 
 2XUXQGHUVWDQGLQJRI WKHXQGHUO\LQJELRORJ\RI$O]KHLPHU¶VGLVHDVH $'KDVEHHQ
steadily progressing; however, this is yet to translate into a successful treatment in humans. 
The use of transgenic mouse models has helped to develop our understanding of AD, not only 
in terms of disease pathology, but also with the associated cognitive impairments typical of 
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AD. Plaques and neurofibrillary tangles are often amongst the last pathological changes in 
AD mouse models, after neuronal loss and gliosis. There is a general consensus that 
successful treatments need to be applied before the onset of these pathologies and associated 
cognitive symptoms. This review discusses the different types of AD mouse models in terms 
of the temporal progression of the disease, how well they replicate the pathological changes 
seen in human AD and their cognitive defects. We provide a critical assessment of the 
behavioural tests used with AD mice to assess cognitive changes and decline, and discuss 
how successfully they correlate with cognitive impairments in humans with AD. This 
information is an important tool for AD researchers, when deciding on appropriate mouse 
models, and when selecting measures to assess behavioural and cognitive change. 
 
Abbreviations 
 
AD - $O]KHLPHU¶VGLVHDVH 
APP- amyloid precursor protein 
BACE1 - ȕ-site amyloid-cleaving enzyme 1 
CAA - cerebral amyloid angiopathy 
DSM - Diagnostic and Statistical Manual of Mental Disorders  
FTD ± fronto-temporal dementia 
hAPP ± human amyloid precursor protein 
KO ± knock out 
MAPT - microtubule associated protein tau 
NFT - neurofibrillary tangles 
OL ± object location 
PSEN - presenilin 
RAM - radial arm maze 
RAWM - radial arm water maze 
SOR - spontaneous object recognition 
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Introduction 
Dementia is a term used to describe a syndrome, caused by various diseases of the 
brain, characterised by significant decline in multiple cognitive areas including memory, 
language, social cognition, executive and perceptual functions. The most recent Diagnostic 
and Statistical Manual of Mental Disorders (DSM-V) introduces the term µMajor 
Neurocognitive Disorders¶, with some changes in criteria compared to DSM-IV [1], 
including more specific details on the degree of impairment observed in the aforementioned 
cognitive domains, and the inability to explain such impairments by any other means [2]. 
Population-EDVHG VWXGLHV VKRZ WKDW $O]KHLPHU¶V GLVHDVH (AD), dementia with Lewy bodies 
and vascular dementia are the most common pathological substrates for dementia [e.g., 3, 4, 
5, 6]. AD is the most common type of dementia and is associated with a decline in cognitive 
abilities, such as memory and visuo-spatial skills. Early-onset familial AD accounts for less 
than 1% of AD diagnoses, and typically occurs before the age of 65 years [7]. Late-onset AD 
most often occurs over the age of 65 years and is much more common. 
Murine models of AD recapitulate aspects of the disease, often through gene 
mutations associated with familial AD, and can powerfully elucidate critical aspects of 
pathogenesis. Although this type of AD is less common, the pathological phenotypes are 
similar to sporadic AD. Extracellular beta amyloid plaques, intracellular hyperphosphorylated 
tau, synaptic and neuronal loss, and neuroinflammation, are all associated with the disease 
[8]. The amyloid cascade hypothesis [e.g., 9, 10] proposed that DP\ORLG $ȕ SODTXH 
deposition is key to the pathogenesis of AD, with tau pathology, inflammation and 
subsequent cell damage as contributing factors. Neuronal and neurotransmitter changes 
IROORZ$ȕGHSRVLWLRQ, leading eventually to cell death. Cognitive decline may be a result of 
neuronal dysfunction from WR[LFVROXEOH$ȕ[11], or inhibited synapse remodelling linked to 
AȕROLJRPHUV>2]. TKHUDSHXWLFWULDOVKDYHWDUJHWHGWKHFOHDUDQFHRI$ȕwith some success in 
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both murine models [13, 14] and in humans [15, 16]. However, LPPXQRWKHUDS\WDUJHWLQJ$ȕ
has not yet translated into improved cognitive functioning [17, 18, 19]. A greater 
understanding of WKHUROHRI$ȕPROHFXODUIRUPVWKHLUWHPSRUDOUROHLQ$'GHYHORSPHQWDQG
their interaction with other pathogenic factors is required.  
Oxidative stress is a key factor in AD, whereby the balance between oxidants and 
antioxidants is disrupted, leading to an excess of oxidants [20, 21]. Several mechanisms may 
contribute towards oxidative stress, including dysfunction of mitochondria [22, 23], 
DFFXPXODWLRQRI$ȕ [22, 24] and hyperphosphorylated tau [25, 26], and neuroinflammation 
[27, 28]. Biomarkers of oxidative stress in AD have been identified; however, a relatively 
recent systematic review by Chang et al. [29] concluded that although serum markers of lipid 
peroxidation are elevated in AD, there is insufficient evidence to justify the use of biomarkers 
as predictors of AD severity or outcome. 
Recent studies have investigated the interacting and modifying factors of the defining 
pathological features of AD; Jonsson et al. [30] reported that a coding mutation (A673T) in 
the APP gene has a protective effect against AD and cognitive decline. Genome-wide 
association studies have reported AD genetic risk factors, with Chapuis et al. [31] recently 
LGHQWLI\LQJ D JHQH )(507 WKDW KDV D UROH LQ UHJXODWLQJ $33 PHWDEROLVP DQG $ȕ
production. Researchers are yet to fully explore the interacting and modifying factors of AD 
pathogenesis using AD mouse models in great detail. 
 The current review will discuss how well, and in what aspects, murine models of AD 
recapitulate the physiological, neuropathological and cognitive changes associated with 
human AD. A complete critical analysis of all AD models and their phenotypes is beyond the 
scope of this review, so the particular focus will be on commonly used amyloid-based 
transgenes (overexpressors of APP and/or its processing enzymes), wild-type human tau or 
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mutant microtubule associated protein tau (MAPT) expressors, and selected combined and 
triple transgenes. 
 
MuriQHPRGHOVRI$O]KHLPHU¶VGLVHDVH 
AD pathology primarily consists of amyloid plaques and neurofibrillary tangles. 
Other pathological features of AD include neuronal and synaptic loss, dystrophic neurites, 
reactive astrocytes, activated microglia and BBB dysfunction [32]. 
Mutations in three genes have been identified as causing autosomal dominant AD 
(amyloid precursor protein ± APP, presenilins ± PSEN1 and PSEN2 WKURXJK DOWHULQJ $ȕ
production, and share similar pathological features to sporadic AD [33]. These gene 
mutations have therefore been the focus of many AD mouse models. Transgenic animals 
based on amyloid production typically express high levels of $ȕ SHSWLGH usually through 
altering the processing of APP [34]. Altered APP processing is usually achieved through 
introduction of human APP, or a presenilin (PSEN) gene mutation, which affects Ȗ-secretase 
enzyme activity, and subsequently alters the FOHDYDJHRI$33WR$ȕ-42 [35, 36]. Cleavage 
RI$33RFFXUVE\ERWKȕ-secretase enzyme (also known as ȕ-site amyloid-cleaving enzyme 1, 
BACE1) at the N-WHUPLQXVRI WKH$ȕSHSWLGH, DQG WKHȖ-secretase enz\PH$ȕ&-terminus) 
activity [36], resulting in a 42 amino acid peptide. This peptide makes up the extracellular 
ILEULOODU $ȕ ZKLFK IRUPV WKH VHQLOH FRPSDFW SODTXHV ZLWK GHQVH cores. The ratio between 
$ȕDQG$ȕUDWKHUWKDQMXVWRYHUDOO$ȕH[SUHVVLRQLVWKRXJKWWREHa significant factor in 
determining plaque load and toxicity [34]. Į-secretase activity is involved in cleavage of APP 
WR$ȕIUDJPHQWVEHWZHHQUHVLGXHVDQGRIWKH$ȕSHSWLGH, UHVXOWLQJLQDWUXQFDWHG$ȕ-
 RU $ȕ-42 fragment. PSEN genes also have several other functions in addition to 
FOHDYDJHRIȖ-secretase, and there is current debate over whether they may be altered by gene 
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mutations leading to AD [37], rather than, or in addition to, chDQJHVWRWKH$ȕ$ȕUDWLR
[38]. 
Single mutations in the PSEN1 or PSEN2 genes cause APP processing E\Ȗ-secretase 
activity to shift towards the more toxiF$ȕ 1-42 rather thDQ$ȕ-40 [39], though these mice 
do not develop plaques unless crossed with APP overexpressor lines [40]. PSEN1 and PSEN2 
gene mutations are functionally similar, although PSEN1 is more severe [41]. 
Neurofibrillary tangles (NFTs) are also a significant hallmark of AD, and are 
composed of hyperphosphorylated forms of tau protein [35]. There are no known MAPT gene 
mutations associated with sporadic AD, but they do occur in frontotemporal dementia 
(FTLD-tau) DQG3DUNLQVRQ¶VGLVHDVHOLQNHGWRFKURPRVRPH)7'3-17; [42]). Tau protein 
binds microtubules stabilising them in the axons, but in some disease states 
hyperphosphorylated tau dissociates from the microtubules and forms pre-fibrillar oligomeric 
and fibrillary aggregates such as NFTs and paired helical filaments (PHFs; [43]). $ȕ
oligomers have been reported to contribute to tau oligomerisation [44]. Improved animal 
models are essential for further understanding the relationship between amyloid and tau 
pathology. Transgenic mice that recapitulate the neurofibrillary tangles therefore express 
either wild-type human tau or mutant MAPT [35]. A number of double-transgenic mice 
models go one step further and attempt to model the functional interaction between APP and 
mutant MAPT expression, to more closely mimic the overall pathology seen in AD, with 
triple transgenes also including a PSEN1 gene mutation. 
AD mouse models that exhibit one or more of the main features of the disease also 
exhibit additional neuropathological changes associated with the disease, such as changes to 
cells within the neurovascular unit [45]. For example astrocytes, which are typically involved 
in cerebral homeostasis, become activated in AD [46] and co-localise with amyloid plaques 
[47]. Early astrocyte damage and dysfunction have been linked to AD pathogenesis [48, 49, 
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50]. Microglia are immune cells that also become activated and co-localise with amyloid 
plaques [51, 52]. 6RPH$'PRXVHPRGHOVDVVRFLDWHGZLWKDOWHUHG$ȕSURGXFWLRQDUHNQRZQ
to develop cerebral amyloid angiopathy (CAA) whereby amyloid deposition builds up on 
arterial walls. It is a pathological feature of AD that can also be found in the elderly without 
AD, and can be associated with cerebral haemorrhage [53]. Mouse models that exhibit CAA 
(such as TgAPP23 and TgCRND8) are useful for assessing small vessel disease and cerebral 
haemorrhage in relation to AD, but interpreting causal links between pathological and 
behavioural phenotypes can be difficult, as symptoms may be due to cerebral abnormalities 
[11]. 
 
Testing cognition in animals 
The hippocampal formation is one of the earliest brain regions to be affected by AD, 
with impairments in working memory and declarative memory amongst the first symptoms to 
be reported by AD patients [54]. Tests of visuo-spatial processing are useful measures of 
cognitive impairment in the disease, however, by the point in which patients undergo 
neuropsychological assessment, neuropathology may have been present for years without 
notable symptomatology [55]. 
Hippocampal-dependent tasks measure early cognitive changes in mouse models of 
neurodegenerative diseases and so will be the sole focus of the review, with a comprehensive 
overview of these and other tasks being reported elsewhere [e.g., 56, 57]. Tasks used in 
mouse models of AD include the Morris water maze [58, 59], the radial arm maze [60], the 
T-maze/Y-maze [61], and the spontaneous object recognition (SOR) task [62].  
The Morris water maze is a test of hippocampal-dependent spatial memory whereby 
rodents typically have to locate a submerged platform using external visual cues (Figure 1). 
Escape latency and/or search path are used as measures of learning acquisition, in which 
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good spatial learning is reflected by a decrease in escape latency and/or the search path used 
to locate the platform. Hippocampal-dependent spatial working memory has been measured 
using a number of paradigms, particularly the radial arm maze (RAM), which involves 
baiting the arms of the maze with food that does not get replenished. Efficient searching 
through reduced entries to previously visited arms suggests the animal remembers where it 
has previously visited. Alternation tasks using the T-maze or the Y-PD]HXWLOLVHWKHDQLPDO¶V
natural exploratory behaviour WR PHDVXUH WKH DQLPDO¶V WHQGHQF\ WR HQWHU WKH OHVV UHFHQWO\
visited arm(s). These spatial alternation tasks require minimal training in contrast to the 
RAM. 
The SOR task relies on URGHQW¶V LQQDWH SUHIHUHQFH IRU QRYHOW\ DV WKH\ GHPRQVWUDWH
recognition for a familiar object through preferential exploration of a novel object. The SOR 
task is not typically hippocampal-dependent, unless the time delay between the sample and 
test phases is increased from minutes to hours [63]. Rodent behavioural tasks are thought to 
rely on the same neural mechanisms as in humans, so they can provide a reliable measure of 
cognitive function in animal models of neurodegeneration that closely reflects the cognitive 
decline seen in human neurological disease. 
 
How well do modeOV RI $O]KHLPHU¶V GLVHDVH UHcapitulate physiological, neuropathological 
and behavioural changes associated with the disease? 
Specific mouse models, categorised as those WKDW RYHUH[SUHVV $ȕ, those with 
mutations affecting secretase processing of APP, and those with NFT pathology (through 
introducing human wild-type tau or mutant MAPT), will now be discussed, considering how 
well they reflect human AD in terms of pathology and cognitive changes. 
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Altering $ȕ through APP processing 
Human APP (hAPP) mutations mainly occur at one or both of the two cleavage sites 
WKDWUHVXOWLQ$ȕSURGXFWLRQ)RUH[DPSOHȖ-secretase cleavage site mutations, such as V717I 
and V717F, DOWHUWKHUDWLREHWZHHQ$ȕDQG$ȕ SURGXFWLRQWRIDYRXUWKHPRUHWR[LF$ȕ 
[34], but many express the K670N/M671L Swedish double mutation at WKH ȕ-secretase 
cleavage site which results in increased BACE cleavage and SURGXFWLRQRI$ȕDQG$ȕ42. 
Others combine both the 6ZHGLVKPXWDWLRQZLWKDȖ-secretase cleavage site mutation [38]. 
 
PDAPP 
The first transgenic mouse model to develop robust amyloid plaque deposition was 
generated by Games et al. [64], and contained human APP (hAPP) with mutations associated 
with familial, early-onset AD (FAD V717F Indiana) using C57Bl/6, DDA/2J and Swiss-
Webster mouse strains (Table 1). The PDAPP mice exhibit amyloid deposition from six to 
nine months of age, with further pathologies characteristic of AD such as dystrophic neurites 
(immunoreactive against phosphorylated tau; [65]), the co-localisation of activated astrocytes 
and microglia with plaques, and a decrease in synaptic density [64]. There is no development 
of NFTs or neuronal loss up to at least 18 months of age [66].  
There is an age-related memory impairment in the SOR task, with all PDAPP mice 
initially performing as well as controls in discriminating between novel and familiar objects 
at three months of age, but by six months onwards, the homozygous PDAPP mice fail to 
successfully discriminate between objects. When tested in the RAM, only homozygous 
PDAPP mice show significant reference memory impairments through entering incorrect 
unbaited arms more often than controls, but PDAPP mice show working memory 
impairments through revisiting previously baited arms more often than controls [35]. Chen et 
al. [67] reported spatial memory impairments in the Morris water maze with three month old 
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PDAPP mice impaired at learning the first platform location. Dodart et al. [68] reported 
sensorimotor impairments in PDAPP mice from three months of age, as they failed to 
habituate to an open field typically exhibited through a decrease in locomotor activity levels 
over time. 
The reported cognitive and behavioural impairments all precede the onset of disease 
pathology in PDAPP mice, which suggests there is early dysfunction to mechanisms linked to 
these impairments, and may contribute to the plaque and cellular pathology which is typical 
of AD. 
 
 Tg2576 
Tg2576 mice were developed by Hsiao et al. [69], overexpressing the Swedish APP 
mutation (K670N/M671L) on a C57Bl/6 x SJL background [35]. These mice show an 
LQFUHDVHLQ$ȕOHYHOVDWVL[ months, and plaque deposition between 9-12 months of age across 
the cortex and hippocampus [70]. These mice recapitulate many of the neuropathological 
features of AD, including astrogliosis [71], microgliosis [72] and dystrophic neurites [71]. 
Similar to the PDAPP mice, there is no observed neuronal loss; however, there is also no 
VLJQLILFDQW GHFUHDVH LQ V\QDSWLF GHQVLW\ > @ $ȕ LQFUHDVHV PDy be linked to synaptic 
dysfunction, if not necessarily synapse loss [73, 75]. 
Tg2576 mice show repetitive exploration behaviours from 10 months of age in the 
spontaneous Y-maze alteration task [69], and from 10 months onwards in the T-maze 
alternation task [75]. Tg2576 mice exhibit VROXEOH$ȕbefore six months of age, but do not 
develop progressive spatial acquisition and memory performance impairments until six 
months onwards [76]. In the SOR task, Tg2576 mice fail to discriminate between novel and 
familiar objects after a 24 hour delay compared to controls at 12-15 months of age [77]. 
Tg2576 mice exhibited greater exploration in an open field [75] and an increased interest in 
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exploring the central areas [78]. Tg2576 mice have also been reported to show increased 
aggression towards cage mates [79]. 
Cognitive impairments in the Tg2576 mice occur much later than the PDAPP mice, 
which may be related to the significant decrease in synaptic density observed in the PDAPP 
mice. Similarly to the PDAPP mice, the cognitive and behavioural impairments in the 
7J PLFH HLWKHU SUHFHGH RU FRLQFLGH ZLWK WKH $ȕ SDWKRORJ\ DJDLQ VXJJHVWLQJ WKHUH Ls 
early dysfunction occurring prior to plaque deposition and glial response. 
 
TgAPP23 
TgAPP23 AD mice were generated using the Swedish double mutation 
.10/ DOWHULQJ WKH ȕ-secretase cleavage site, and the London (V717I) mutation 
DOWHULQJ WKHȖ-secretase cleavage site, on a C57Bl/6 x DBA/2 background [80]. These mice 
overexpress hAPP across the hippocampus and cortex and are notable for their 
cerebrovascular phenotype [81]. Amyloid deposition is present from six months of age and 
substantial by 12 months, particularly in cerebral vessels which progressively decreases 
cerebral blood flow and alters vessel morphology [82, 83]. TgAPP23 mice also display 
reactive gliosis and astrocytosis, dystrophic neurites, and synaptic loss [81], as well as a 
degree of neuronal loss in older TgAPP23 mice [84]. 
TgAPP23 mice show spatial impairments in water maze latencies and path lengths 
from three months of age prior to substantial plaque deposition [85]. In the SOR task, 
TgAPP23 mice fail to discriminate between novel and familiar objects after a 24 hour delay 
at three-four months of age [86]. Both SOR and water maze task impairments occur from 
around three months of age, therefore, preceding amyloid deposition. This is similar to the 
PDAPP and Tg2576 mice, though with slightly different ages of onset. 
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TgAPP23 mice exhibit a cerebrovascular phenotype making them a useful model for 
AD with CAA, but it is unclear how much of the neuropathology and cognitive profiles can 
be attributed to the hAPP mutation or the cerebrovascular changes [11]. 
TgAPP23 mice exhibit a decrease in exploratory behaviour in the open field, at six-
eight weeks, three and six months of age, whilst also showing significant impairments 
relative to control animals on the rotorod at three and six months [87]. TgAPP23 mice have 
also been reported to show increased aggression from six months of age, after the onset of 
both amyloid plaques and other discussed behavioural impairments [88]. 
 
TgCRND8 
TgCRND8 mice were developed on a C57Bl/6 x C3H background and contained both 
the APP Swedish double mutation (K670N-M671L), and the V717F Indiana mutation [35]. 
These mice present with $ȕ deposition at three months of age, with dense core plaques 
present by five months in the cortex and hippocampus [89, 90], spreading to the cerebellum 
and brainstem by eight to nine months of age [11], which is associated with increased 
inflammatory response [91]. In addition, astrocytic gliosis and microglial activation in 
regions around plaques have been reported [90]. 
Chishti et al. [90] reported that these mice have significant acquisition impairments in 
hidden platform testing at 11 weeks, with longer swim paths and search latencies compared 
to controls. In addition, TgCRND8 mice show spatial reference memory impairments at six 
to eight months of age, but were able to overcome this impairment when the hidden platform 
was visibly cued [92]. 
At three to five months of age, TgCRND8 mice fail to discriminate between novel 
and familiar objects on the SOR task with a one hour delay [93], and in the Y-maze task, 
TgCRND8 mice perform comparably to controls up to around 11 months of age, 
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demonstrating intact short-term spatial memory capacity [94]. Overall, and similarly to the 
previously discussed AD models, any significant cognitive impairments reported in the 
TgCRND8 mice coincide with amyloid deposition, occurring at an early age of around three 
months. +RZHYHU WKH$ȕSDWKRORJ\GRHVRFFXUDWD\RXQJHUDJHFRPSDUHGWRWKHSUHYLRXV
models, so the timeline from when the cognitive impairments are observed, to when amyloid 
deposition occurs, is much shorter, almost occurring simultaneously. 
 
 J20 
The J20 transgenic moXVH IHDWXUHV D KLJK OHYHO RI $ȕ1-42 overexpression resulting 
from the introduction of both the Swedish (K670N and M671L) and Indiana (V7171F) hAPP 
mutations in a C57Bl/6 x DBA2J background. Diffuse amyloid deposits appear from five to 
seven months of age in the hippocampus and the neocortex, with larger neuritic plaques 
appearing after nine months of age (Figure 2). J20 mice also exhibit a decrease in 
synaptophysin-immunoreactivity indicating changes in synaptic function [11]. J20 mice are 
also a useful epilepsy model, due to abnormal neural hyperexcitability [95], and 
cerebrovascular function and neurovascular coupling in relation to neurodegeneration [e.g., 
96, 97]. 
On the SOR task, J20 mice successfully discriminate between novel and familiar 
objects after a one hour delay up to 15-16 months of age [98], but are unable to recognise 
familiar objects after a four hour delay at six to eight months of age [99]. When the delay is 
extended to 24 hours, J20 mice are impaired from as early as four months old [100]. Overall, 
these findings suggest that J20 AD mice are able to successfully recognise a previously 
encountered object following a delay of up to one hour, but not after a delay of over four 
hours. 
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 Palop et al. [101] reported that J20 mice aged six to nine months of age are impaired 
in water maze hidden platform location as well as spatial location retention in probe trials. An 
alternative measure of spatial memory that relies on the DQLPDO¶V natural exploratory 
behaviour is the object-location (OL) task (a spatial variant of the SOR paradigm). AD mice 
with APP mutations show impairments on the OL from around five months of age [102]. 
Unlike the previously discussed AD models, the age of onset for spatial memory impairments 
in the water maze is not as early. Spatial memory impairments in the OL task are observed at 
a slightly younger age, so it can be concluded that, overall, impairments observed on both 
recognition and spatial memory appear to coincide closely with the deposition on amyloid in 
the hippocampus and cortex, from around four months onwards. 
 
Secretases 
Specific mutations in the PSEN genes (PSEN1 and PSEN2; [103, 104] result in 
FKDQJHVLQȖ-secretase activity leading to preferential SURFHVVLQJRI$ȕ-42 fragments. Most 
PSEN gene mouse models are derived from PSEN1 mutations.  
 
APP + PSEN1 
Holcomb et al. [40] crossed the PSEN1 transgene (M146L) with hAPP Tg2576 mice, 
and at four to five months of age APP + PSEN1 mice KDGGHWHFWDEOHLQVROXEOH$ȕ At six to 
eight months of age, APP + PSEN1 mice show elevated levels of $ȕ compared to single 
transgenic Tg2576 littermates [40]. Spatial memory impairments appear as early as 12-14 
weeks of age, with APP + PSEN1 mice showing a significant reduction in the number of 
alternations on the Y-maze spatial task [105]. Arendash et al. [106] further supported these 
findings, reporting that APP + PSEN1 mice showed a significant reduction in the number of 
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alternations in the Y-maze task at five to seven months of age, but also showed impairments 
in acquisition of spatial locations in the water maze at 15-17 months of age.  
15-17 month old APP + PSEN1 mice exhibited sensorimotor deficits through a 
significant impairment on a balance beam test, and increased activity in the open field [106]. 
A more recent study by Wang et al. [107] measured sensorimotor gating in the APP + PSEN1 
mice at three, seven and 22 months of age, using the prepulse inhibition (PPI) of the startle 
response (attenuated startle response from a preceding stimulus). PPI was found to be lower 
in seven and 22 month old APP + PSEN1 mice compared to age-matched controls, with the 
seven month old APP + PSEN1 mice also exhibiting memory impairments in the water maze 
task DQGLQFUHDVHG$ȕ plaque deposition compared to three month old APP + PSEN1 mice. 
&RUUHODWLQJWKHRQVHWRI$ȕpathology and impairments in spatial memory in the water 
maze suggest that these phenotypes are linked, with onset occurring around six to seven 
months of age. However, spatial memory performance in the Y-maze reveals impairments 
from as early as three months of age, highlighting how task-specific demands can vary in 
sensitivity. 
 
 BACE1 KO x APP 
Luo et al. [108] developed the BACE1 knock out (KO) on a hAPP Tg2576 
background. BACE1-/-Tg2576+ SKHQRW\SLFDOO\ VKRXOG EH µQRUPDO¶ LQ WKDW WKH\ VKRZ QR
significant disease-associated pathology. These mice do not develop plaques or produce 
VROXEOH$ȕSHSWLGHV [109]. In the Y-maze alternation task, BACE1-/- Tg2576+ mice at four to 
six months of age performed as well as wild-type controls and significantly better than 
Tg2576 mice who exhibit brain amyloid $ȕ (but not plaque deposition) at this age. These 
results suggest that BACE1 deficiency in a hAPP transgenic mouse model results in 
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improved performance on the Y-maze alternation task, which PD\EHOLQNHGWRUHGXFHG$ȕ
levels. 
 
Tau and triple transgenes 
Most transgenic mouse models used to investigate tau and the formation of NFTs 
involve either introducing a gene for human wild-type tau, or mutant MAPT [35]. It is 
important to note that single transgenic mice with FTD-associated tau (e.g., the JNPL3 line 
expressing the P301L FTD-associated tau mutation) are better understood as models of 
fronto-temporal dementia (FTD), rather than AD [38]. A number of studies have also 
modelled tau propagation through transgenic lines that overexpress P301L restricted to 
regions such as the entorhinal cortex where neurons are first affected by NFTs [110], or 
through injecting tau preformed fibrils into specific brain regions of PS19 transgenic mice 
overexpressing human P301S mutant tau, for example [111]. 
 
TAPP 
Lewis et al. [112] crossed the hAPP Tg2576 mouse line with the JNPL3 mouse line 
expressing the most common FTD-associated human tau mutation (P301L), forming the 
TAPP bigenic line. The TAPP mice develop $ȕ plaque deposition comparable to Tg2576 
mice and as early as six months of age [112], but the NFT pathology is more severe than 
JNPL3 mice, suggesting the APP pathology may contribute towards exacerbating tangle 
formation [112]. Cognitive performance is not widely reported in this model, but they do 
have various motor disturbances [112]. Yuzwa et al. [113] recently reported TAPP mice were 
impaired on the water maze task at seven to eight months of age, which is at a slightly later 
DJHRIRQVHWWR$ȕGHSRVLWLRQDQGLQFRQWUDVWWRSUHYLRXVO\GLVFXVVHG$'PRGHOV. 
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Tg2576/VLW tau 
Amyloid overexpressing Tg2576 mice were crossed with VLW mice with mutant 4R 
MAPT [114] containing a triple mutation (G272V, P301L, R406W) on a C57Bl/6 x CBA 
background. These mice exhibit ZLGHVSUHDG$ȕaccumulation initially at nine months of age, 
with widespread deposition, and neuronal loss in the entorhinal cortex and CA1 region of the 
hippocampus from 16 months of age [114]. Spatial memory tested in the Morris water maze 
reveals longer escape latencies compared to wild-type controls initially at nine months of age, 
but predominantly from 16 months of age [114]. The spatial memory impairments in the 
ZDWHUPD]HDUHILUVWREVHUYHGDWDFRPSDUDEOHDJHRIRQVHWUHODWLYHWR$ȕGHSRVLWLRQEXWWKLV
is still at a later age of onset compared to previously discussed AD models. 
 
3xTgAD 
The 3xTgAD mouse line was developed by Oddo et al. [115], who generated a triple 
transgenic model by coinjecting two transgenes containing APP (Swedish) and MAPT P301L 
FTDP-17 mutations into embryonic cells from PS1M146V knock-in mice. 3xTgAD mice 
exhibit increased levels of $ȕ1-DQG$ȕ1-42, and NFTs. Amyloid plaques are present as 
early as three months of age, with NFTs appearing much later at 12 months of age in the 
hippocampus and cortex [115]. These mice also have altered synaptic function which 
progresses with age [115], and spatial memory impairments on the water maze from six 
months of age [116]. Davis et al. [117] reported intact recognition memory at 11 months of 
DJH GHVSLWH WKH SUHVHQFH RI LQWUDFHOOXODU $ȕ IURP ILYH PRQWKV ,Q DGGLWLRQ [7J$' PLFH
showed impairments on the T-maze task (being unable to successfully distinguish between 
novel and familiar arms), and the radial arm water maze (RAWM) from between six and nine 
months of age [118]. 2YHUDOO $ȕ GHSRVLWLRQ RFFXUV HDUO\ LQ [7J$' PLFH SULRU WR DQ\
significant cognitive impairments, which are reported from around six months of age. This is 
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in contrast to the previously discussed AD models. NFTs also develop later, at around 12 
months of age. Though 3xTgAD mice present with the two main features of AD, these 
findings suggest poor correlation between behavioural impairments and disease pathology, 
SHUKDSVEHFDXVH$ȕDQGWDXGHYHORSLQGHSHQGHQWO\RIRQHDQRWKHU. 
 
Translation into therapeutic developments 
There are currently only a select number of drugs available to treat AD, focusing on 
alleviating symptoms, with no new drugs being approved since 2003. No drug has yet been 
identified to significantly alter the course of the disease, and translate successfully into 
clinical applications. This may be due to significant differences between rodent models and 
humans in terms of how they metabolise the drugs, how the drugs act upon certain 
mechanisms, and fundamental differences in neural circuitry between species [119]. 
 Immunotherapy has been investigated preclinically in AD mouse models as a 
SRWHQWLDO WKHUDSHXWLF VWUDWHJ\ WKURXJK SUHYHQWLQJ $ȕ DJJUHJDWLRQ. For example, 
administration of the monoclonal antibody bapineuzumab in PDAPP resulted in a reduction 
RIERWKVROXEOHDQGLQVROXEOHOHYHOVRI$ȕ[120]. Immunotherapies targeting amyloid plaques 
have progressed to clinical trials, showing some promising reductions in rate of cognitive 
decline [121]DQGOHYHOVRI$ȕDQGWDXIROORZLQJ neuropathological investigations [122], but 
no trials have shown results that are both significantly efficacious and non-harmful. For 
example, a recent meta-analysis highlighted the lack of clinical efficacy of bapineuzumab 
[123] which failed Phase III trials, alongside similar monoclonal antibody solanezumab 
[124]. 
BACE1 is another therapeutic target, with administration of TAK-070 (a non-peptidic 
BACE1 inhibitor) to Tg2576 mice resulting in a reduction of both soluble and LQVROXEOH$ȕ 
and a reduction in cognitive impairments [125]. However, promising BACE1 inhibitor 
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verubecestat has recently failed in clinical trial, though a trial with patients at an earlier stage 
of the disease continues [126]. Hung and Fu [127] have recently published a comprehensive 
review of AD drugs in clinical trials up to June 2017, including the therapeutic targets, trial 
status, and clinical outcomes. 
Stem cells have been investigated as a potential therapeutic strategy for AD. 
Administration of haplotype matched murine neuronal stem cells to aged 3xTgAD mice 
reduced cognitive impairmentsEXWKDGQRVLJQLILFDQWHIIHFWRQ$ȕRUWDXSDWKRORJ\ [128]. 
There have also been recent advances in the use of optogenetics, a technique which 
modulates neuronal activity, as a therapeutic approach for neurodegenerative diseases, 
including AD [129]. However, this research is currently in the very early stages of research. 
In summary, a number of therapeutic strategies have been developed in AD mouse 
models and have shown promising results LQ WHUPV RI UHGXFLQJ $ȕ RU WDX IRU H[DPSOH
showing that these models are good for recapitulating disease pathology. However, none of 
these strategies have yet successfully translated to clinical outcomes in AD patients, so there 
is a need for more advanced animal models that better model disease complexity. 
 
Discussion 
No one model provides an ideal and complete characterisation of AD as observed in 
humans, however, different models are useful for answering questions about specific aspects 
of the disease.  
Within each type of AD model there are variations in terms of the onset of 
pathological features and cognitive decline, of which some can be accounted for by 
background strains as well as differing baseline abilities in terms of learning, memory and 
locomotion [39]. Even with AD models of the same genetic background, many cognitive tests 
are sensitive to small variations in task protocol, which can yield contrasting results [130]. 
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Rodents are nocturnal and do not primarily rely on vision, but olfaction, which raises issues 
around their abilities to perform in tasks such as the Morris water maze [131]. Mice, in 
particular, are known to perform poorly in the water maze compared to rats, due to tendencies 
to swim nearer to the wall (a classic hallmark of anxiety; [132] and to be more buoyant [133]. 
The age of the animals is also a determining factor in water maze performance [134], which 
may be related to an age-related decline in motor abilities.  
No AD mouse model exhibits the full range of pathological phenotypes, making it 
difficult to correlate cognitive decline and pathological changes. Only a small number of AD 
models exhibit neuronal loss [39], with it being rarely reported in APP models, such as 
PDAPP and Tg2576 [67, 72], but more often reported in APP models combined with PSEN1 
gene mutations [135]. $ȕimpairs synaptic function, which is likely to be a major contributor 
to the cognitive impairments reported [36]. Studies have described a loss in synaptophysin-
immunoreactivity around compact plaques in both PDAPP and Tg2576 mice, indicating 
changes to synapse functiRQ UHODWLQJ WR $ȕ >]. SROXEOH $ȕ PD\ FRQWULEXWH WRZDUGV
cognitive impairments, which would account for why they are observed prior to compact 
plaque deposits [77]. Pathological and behavioural features need consideration when 
selecting an AD model to test a specific hypothesis, and will depend on the precise 
mechanisms being investigated. 
 It is not clear how accurately the time course of amyloid plaque deposition and 
cognitive decline reflects human AD. Behavioural impairments are often reported prior to 
plaque deposition DFURVV$'PRXVHPRGHOVEXWLWLVOLNHO\WKDW$ȕSDWKRORJ\LVSUHVHQWSULRU
to the onset of cognitive impairments in humans [136]. It may, however, be likely that subtle 
changes in cognition occur prior to patients reporting the first notable changes with their 
physician. 
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Transgenic mice expressing both amyloid and tau pathology (e.g., TAPP and 
3xTgAD) may seem like the ideal models to study human AD as they more closely reflect the 
disease. Although these mice present with the two main features of AD, these pathologies are 
reported as developing independently [38], and so do not fully mimic the disease progression 
seen in humans. 
A number of emerging hypotheses linking other health conditions to dementia and 
AD present an opportunity for AD models to be utilised as models for other diseases. For 
H[DPSOH UHFHQW VWXGLHV VXJJHVW WKDW $ȕ PD\ SOD\ D UROH LQ SURPRWLQJ Ferebrovascular 
atherosclerosis [137], which would make an APP mouse model suitable for studying this 
relationship and a number of other cerebrovascular and neurodegenerative diseases, 
particularly as such conditions rarely present independently in humans. 
Two genetic variations which are important risk factors for sporadic AD are the allelic 
variations of apolipoprotein (APOE), and the R47H allele of the triggering receptor expressed 
on myeloid cells 2 (TREM2; [138]). $32(FRORFDOLVHVZLWK$ȕDQGPLFURJOLa. Mice that are 
haploinsufficient for human APOE show a significant decrease in plaque deposition in 
APP/PSEN1 (L166P) and J20 mice [139, 140], and APOE-knockout mice have been reported 
WRFOHDU$ȕ faster than control mice [141]. Disrupting the iQWHUDFWLRQEHWZHHQ$32(DQG$ȕ 
may be DYLDEOHSRWHQWLDOWKHUDSHXWLFDSSURDFKWRUHGXFH$ȕ deposition. 
There are conflicting reports regarding the effect of 75(0 RQ RYHUDOO $ȕ plaque 
deposition which has been characterised in the APP/PSEN1 and 5xFAD mouse models [142, 
143]. Ulrich et al. [144] reported that TREM2 haploinsufficient APP/PSEN1 mice of three 
and seven months of age VKRZHGQRVLJQLILFDQW$ȕGHSRVLWLRQLQWKHFRUWH[ Further research 
supports these findings with Jay et al. [145] reporting that four month old TREM2-/- 
APP/PSEN1 mice VKRZHG QR VLJQLILFDQW FRUWLFDO $ȕ GHSRVLWLRQ, and a decrease in 
hippocampal Aȕdeposition compared to TREM2+/+ APP/PSEN1 mice (26). In comparison, 
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Wang et al. [146] reported that eight month old TREM2-/- 5xFAD mice exhibited an increase 
in hippocampal Aȕ deposition, with no significant effect on cortical Aȕ. Further work is 
needed to elucidate the roles of APOE and TREM2 gene variations in AD, and refining 
animals models will be key to progressing how the function of these genes relate to certain 
pathological features of AD. 
Touchscreen technology [147] could present as a way of standardising and improving 
rodent cognitive and behavioural tests. A range of computer-automated cognitive tasks have 
been developed for rodents which are designed to mimic the neuropsychological tasks used 
with humans, improving their translational capability. Such tasks are carried out in the same 
apparatus with the same type of stimuli, improving the ability to compare performance across 
tasks. Romberg et al. [148] reported that TgCRND8 mice showed no impairment on a visual 
discrimination test, but were impaired on a test of object recognition, even with a short delay 
of one minute. It is possible that the touchscreen version of the object recognition task is 
more difficult than the standard version, potentially due to rodents naturally being more 
dependent on olfaction than visual acuity, but the technology remains promising. 
There have been varying results regarding the effect of sexual differences on AD 
mouse model phenotypes, but it is necessary to understand how such differences may 
contribute to making one sex more vulnerable or protected from disease. Research suggests 
that female AD mice have an increased vulnerability to AD phenotypes, but Dubal et al. 
[149] propose this may be more closely related to a greater beneficial effect of male 
hormones, and a more deleterious effect of female hormones in the brain of AD mouse 
models. 
Developments in genome editing technology known as CRISPR/Cas9 allows for mice 
to be genetically engineered much more efficiently [150], as multiple gene variations can be 
introduced simultaneously. This technology is particularly significant for developing mouse 
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models of late-onset AD, which is likely to involve multiple gene variations. Improved 
predictive models should lead to better translation between preclinical and clinical studies, 
particularly for the more common late-onset AD. 
 
Conclusion 
Mouse models of AD continue to be a central component in furthering our 
understanding of the disease and identifying new therapeutic targets for existing and novel 
compounds. It is important, however, to treat AD models as a reductionist tool for 
understanding the pathogenesis of AD, and research should be guided by human studies to 
look for the causal relationships human work cannot often provide. 
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Figure legends 
Figure 1 ± 7HVWDSSDUDWXV¶IRUDVHULHVRIURGHQWFRJQLWLYHWDVNVD7KH0RUULVZDWHUPD]H
Animals are required to locate a submerged (hidden) platform. Escape latency and/or search 
path are used as measures of spatial memory. Memory impairment is demonstrated through 
no decrease in escape latency. b) Radial arm maze. The animal begins in the centre of the 
maze, with each arm baited with food. The animal can explore these arms and consume the 
food reward, but the food is not replenished. Spatial working memory is assessed through the 
number of times unbaited arms are re-entered. Memory impairment is demonstrated when 
unbaited arms are repeatedly visited. The dashed lines represent the line to be crossed for an 
arm entry to be counted. c) T-maze alternation task. During a sample phase, the animal 
begins in the start arm and is forced to enter either the right or left arm (in tis example, the 
left), receiving a food reward. For the test phase, the animal again begins in the start arm, but 
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has the choice between previously entered arm and the novel arm. The animal receives a food 
reward for entering the arm not previously visited during the sample phase. Memory 
impairment is demonstrated if the animal fails to alternate between the arms from sample to 
test phase. The dashed line represents the door blocking entry to the right arm during the 
sample phase. d) Y-maze alternation task. The animal begins in the centre of the maze in this 
continuous version of the alternation task. For a period of time (e.g., 10 minutes) the animal 
can freely explore the three arms of the maze ODEHOOHGKHUHDVµ$¶µ%¶DQGµ&¶. Memory 
impairment is demonstrated if the animal fails to display a tendency to alternate between the 
less visited arms.  e) Spontaneous object recognition. Animals can freely explore two copies 
of an object in an open field in a sample phase. Following a delay (of minutes or hours), the 
animal is returned to the open field and exposed to a copy of the sample object and a novel 
object in the test phase. Recognition of the familiar object is shown through greater 
exploration of the novel object over the familiar object. Memory impairment is demonstrated 
through equal exploration of both objects at test. 
 
Figure 2 ± Glial pathology associated witK$ȕSODTXHVLQWKHKLSSRFDPSXVRIDPRQWKROG
hAPP--PRXVH$ȕSODTXHV(UHGDUHDVVRFLDWHGZLWKDUHDFWLYHDVWURF\WHV*)$3
brown) and (b) microglia (Iba-1, brown). Scale bar represents 50µm. Images are contrast 
enhanced. 
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Table 1. Timeline of onset of amyloid pathology and cognitive test impairments in transgenic 
mouse models of AD. 
Transgenic 
mouse model 
Mutation Amyloid 
deposition 
SOR Water maze T-maze Y-maze 
PDAPP APP (Indiana 
V717F) 
 
6-9 months 6 months 3 months   
Tg2576 APP (Swedish 
K670N-M671L) 
 
9-12 months 12-15 
months 
6 months 10 months 10 months 
TgAPP23 APP (Swedish 
K670N-M671L) 
 
6-12 months 3-4 months 3 months   
TgCRND8 
 
 
 
 
 
APP (Swedish 
K670N-M671L 
and Indiana 
V717F) 
3-5 months 3-5 months 3 months   
J20 APP (Swedish 
K670N-M671L 
and Indiana 
V717F) 
 
5-7 months 4 months 6-9 months   
APP + 
PSEN1 
APP (Swedish 
K670N-
M671L), 
PSEN1 M146L 
 
6-8 months  15-17 months  3 months 
TAPP 
 
 
 
 
APP (Swedish 
K670N-
M671L),  
MAPT P301L 
6 months  7-8 months   
Tg2576/VL
W tau 
 
APP (Swedish 
K670N-
M671L), 
G272V, MAPT 
P301L, R406W 
 
9 months  16 months   
3xTgAD APP (Swedish 
K670N-
M671L), MAPT 
P301L, PSEN1 
M146V 
5 months Intact at 11 
months 
 6-9 months  
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